美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

基因编辑

511.11

+51.6411.24%

涨家数：5

跌家数：- -

平家数：- -

市盈率：- -

高：512.77

开：463.10

低：463.10

收：459.47

成交量：3,569.65万

成交额：5.32亿

市值：104.29亿

流通市值：100.00亿

数据加载中...

Crispr Therapeutics Ag盘中异动早盘股价大涨5.28%

Editas Medicine, Inc.盘中异动早盘大幅拉升5.51%报2.87美元

Intellia Therapeutics完成遗传性血管性水肿药物Lonvoguran Ziclumeran (Lonvo-Z)全球3期临床试验Haelo研究的患者招募

Intellia Therapeutics, Inc.盘中异动早盘股价大涨5.54%报12.95美元

Editas Medicine, Inc.盘中异动早盘大幅下跌5.06%

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK4556/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4556","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"基因编辑","latestPrice":511.1056,"timestamp":1758225599999,"preClose":459.46536,"halted":0,"volume":35696462,"delay":0,"changeRate":0.112392,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":51.640228,"latestTime":"09-18 16:00:00 EDT","open":463.0955,"high":512.772,"low":463.0955,"amount":531728133.688402,"amplitude":0.108118,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1758288600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":2.650979,"peRate":-5.653711,"turnoverRate":0.058415,"increases":5,"decrements":0,"flats":0,"marketCap":10428645456,"floatMarketCap":9999505104},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","high":512.772,"amplitude":0.108118,"preClose":459.46536,"low":463.0955,"pbRate":"2.650979","latestPrice":511.1056,"volume":35696462,"delay":0,"open":463.0955,"prevYearClose":376.62552,"prevWeekClose":432.3117,"prevMonthClose":390.8961,"prevQuarterClose":368.039,"fiveDayClose":435.8584,"twentyDayClose":389.6485,"sixtyDayClose":361.3764,"secType":"PLATE","market":"US","turnoverRate":0.058415,"peRate":-5.653711,"marketCap":10428645456,"floatMarketCap":9999505104,"timestamp":1758225599999,"nameCN":"基因编辑"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4556\",,,,undefined,":{"bkCode":"BK4556","up":5,"down":0,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4556\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2568400073","title":"Crispr Therapeutics Ag盘中异动 早盘股价大涨5.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2568400073","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568400073?lang=zh_cn&edition=fundamental","pubTime":"2025-09-18 21:53","pubTimestamp":1758203629,"startTime":"0","endTime":"0","summary":"北京时间2025年09月18日21时53分，Crispr Therapeutics Ag股票出现异动，股价快速拉升5.28%。Crispr Therapeutics Ag股票所在的生物技术行业中，整体涨幅为0.67%。Crispr Therapeutics Ag公司简介：CRISPR Therapeutics是一家基因编辑公司，专注于开发基于Crispr/Cas9的疗法。Crispr/Cas9代表成簇的规则间隔短回文重复序列/Crispr相关蛋白9，是精确改变基因组DNA特定序列的革命性技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091821534995369f21&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091821534995369f21&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1861559042.SGD","BK4588","LU1861558580.USD","BK4539","LENZ","CRSP","BK4611","BK4556","BK4585","BK4139","BK4007"],"gpt_icon":0},{"id":"2568234260","title":"Editas Medicine, Inc.盘中异动 早盘大幅拉升5.51%报2.87美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2568234260","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568234260?lang=zh_cn&edition=fundamental","pubTime":"2025-09-18 21:31","pubTimestamp":1758202306,"startTime":"0","endTime":"0","summary":"北京时间2025年09月18日21时31分，Editas Medicine, Inc.股票出现异动，股价急速上涨5.51%。Editas Medicine, Inc.股票所在的生物技术行业中，整体涨幅为0.30%。其相关个股中，89Bio, Inc.、Aptevo Therapeutics Inc.、Nanobiotix涨幅较大，Aptevo Therapeutics Inc.、Psyence Biomedical Ltd.、Biocardia, Inc.较为活跃，换手率分别为1787.19%、617.67%、244.86%，振幅较大的相关个股有Replimune Group, Inc.、Aptevo Therapeutics Inc.、Curanex Pharmaceuticals Inc，振幅分别为17.51%、16.31%、8.51%。Editas Medicine, Inc.公司简介：Editas Medicine Inc 是一家临床阶段基因组编辑公司，致力于开发具有潜在变革性的基因组药物来治疗各种严重疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250918213146a728723c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250918213146a728723c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","EDIT","BK4556"],"gpt_icon":0},{"id":"1175675607","title":"Intellia Therapeutics完成遗传性血管性水肿药物Lonvoguran Ziclumeran (Lonvo-Z)全球3期临床试验Haelo研究的患者招募","url":"https://stock-news.laohu8.com/highlight/detail?id=1175675607","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175675607?lang=zh_cn&edition=fundamental","pubTime":"2025-09-18 19:30","pubTimestamp":1758195054,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics已完成其治疗遗传性血管性水肿药物Lonvoguran Ziclumeran (Lonvo-Z)的全球3期临床试验Haelo研究的患者招募工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","NTLA","BK4535","LU1861558580.USD","BK4139","LU1861559042.SGD","BK4585","BK4556"],"gpt_icon":0},{"id":"2568472518","title":"Intellia Therapeutics, Inc.盘中异动 早盘股价大涨5.54%报12.95美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2568472518","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568472518?lang=zh_cn&edition=fundamental","pubTime":"2025-09-17 21:31","pubTimestamp":1758115909,"startTime":"0","endTime":"0","summary":"北京时间2025年09月17日21时31分，Intellia Therapeutics, Inc.股票出现波动，股价快速上涨5.54%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.16%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics 是一家基因编辑公司，致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系，以推进其产品线的发展，其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250917213149a4cbc586&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250917213149a4cbc586&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4535","BK4539","BK4139","BK4588","LU1861559042.SGD","LU1861558580.USD","BK4585","NTLA","LENZ","BK4007","BK4556"],"gpt_icon":0},{"id":"2568484109","title":"Editas Medicine, Inc.盘中异动 早盘大幅下跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2568484109","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568484109?lang=zh_cn&edition=fundamental","pubTime":"2025-09-16 21:54","pubTimestamp":1758030886,"startTime":"0","endTime":"0","summary":"北京时间2025年09月16日21时54分，Editas Medicine, Inc.股票出现异动，股价大幅下挫5.06%。Editas Medicine, Inc.股票所在的生物技术行业中，整体跌幅为0.10%。其相关个股中，Surrozen Inc C/Wts 01/08/2031 、Aptevo Therapeutics Inc.、Adaptimmune Therapeutics Plc涨幅较大，Aptevo Therapeutics Inc.、Silo Pharma, Inc.、Enveric Biosciences, Inc.较为活跃，换手率分别为2221.24%、104.32%、80.41%，振幅较大的相关个股有Aptevo Therapeutics Inc.、Adaptimmune Therapeutics Plc、Ethzilla Corporation C/Wts 06/11/2025，振幅分别为40.97%、31.68%、23.68%。Editas Medicine, Inc.公司简介：Editas Medicine Inc 是一家临床阶段基因组编辑公司，致力于开发具有潜在变革性的基因组药物来治疗各种严重疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250916215447979642c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250916215447979642c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4556","BK4139","EDIT"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}]}}